KNOWLEDGE BANK

Interviews

Ensuring Ethics in AI-Driven Drug Safety

Senior Director of Pharmacovigilance and Risk Management at Curis Inc.
Ashish Jain is Senior Director of Pharmacovigilance and Risk Management at Curis Inc with over years of experience in drug safety He is also leading the Innovation Working Group at the North American Society of Pharmacovigilance NASoP his expertise in combining technological innovation with patient safety makes him uniquely qualified to address the ethical challenges of AI implementation in pharm...

Articles

Design of Self-antibacterial and Biocompatible Titanium Surfaces for Biomedical Applications

Metals and alloys are the first generation bioinert biomaterials These materials possess excellent mechanical strength low elastic modulus and good corrosion resistance Titanium Ti and its alloys are one of the commonly used metallic biomaterials for orthopedic applications eg bone plates screws dental implants and prostheses Both bulk and surface properties

Research Insights

Phenotype to Genotype: A New and Rapid Approach Using Whole-genome Sequencing

Forward genetic screening is a powerful approach to assign functions to genes and can be used to elucidate the many genes whose functions remain unknown A key step in forward genetic screening is mapping

Case Studies

Novel Vaccines - Heat Stable Anthrax Vaccine

Challenge Existing approved Anthrax vaccines are based on cellfree filtrates of disintegrated cells of Bacillus anthracis adsorbed onto an aluminiumhydrogel adjuvant A number of side effects are attributed to these vaccines including poor safety profile and a low immunogenicity necessitating repea

Techno Trends

Biogen Introduces Breakthrough Salanersen Therapy for Treating Spinal Muscular Atrophy

Biogen has introduced salanersen for the treatment of spinal muscular atrophy SMA a rare genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Tiny Vesicles, Big Impact

Disha Marwaha

Dr. Disha Marwaha received her PhD in biological sciences from CSIR-Central Drug Research Institute (CSIR-CDRI), India in 2024. She is currently an Assistant Professor at the GLA University, Mathura. She has more than 20 publications in international peer-reviewed Journals. She is an expert in formulation and development, nanomedicine and pharmacokinetics focusing on innovative therapeutic and targeted drug delivery systems.

Neha Singh

Dr. Neha Singh received her Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI), India, in 2025. She is currently an Assistant Professor at the Lloyd School of Pharmacy, Greater Noida. Dr. Singh has contributed extensively to the field of pharmaceutical sciences, with many publications, patents, and book chapters in internationally recognised peer-reviewed journals. Her primary research interests include formulation development, nanomedicine and pharmacokinetics, with a focus on innovative therapeutic strategies and targeted drug delivery systems. Dr. Singh’s work reflects her commitment to advancing precision medicine and developing next-generation solutions for healthcare.

2

Revolutionising Tuberculosis Treatment test

Ashok Aspatwar

Ashok Aspatwar, MS, PhD, is an Adjunct Professor at Tampere University, Finland. His research focuses on carbonic anhydrases in Mycobacterium tuberculosis persistence and anti-TB drug development, using molecular biology, medicinal chemistry, and AI-driven bioinformatics to explore novel therapeutic pathways and target mechanisms in TB.

Rarchita Sharma

Rarchita Sharma, M. Pharm, is a researcher at SVKM's Institute of Pharmacy, specialising in novel drug delivery for CNS disorders. She has published seven papers on topics like regulatory filings, AI in stroke care, and cardiovascular drugs, aiming to advance therapeutic innovations in pharmaceutical sciences.

3

Precision medicine for Alzheimer’s Disease

Dr. Parmi Tripathi

Dr Parmi is a scientific researcher and an expert medical writer with Ph.D specialising in neurosciences. With an extensive pharmaceutical and healthcare industry experience, she excels at driving innovation. Focused at patient’s centricity, she has played key role in developing innovative medicines that makes meaningful impact on patient’s lives. Dr Parmi has made significant contribution at establishing a patented mouth-dissolving strip (MDS) manufacturing facility. With proven expertise in novel product development, her strong emphasis on quality manufacturing has led to structuring of quality documentation practices for this novel & patented MDS technology aligned with regulatory standards.

Dr Parmi has made significant contributions in field of neuroscience research with multiple acclaimed publications. A distinguished medical writer, she serves as editorial board member and peer reviewer in prestigious journals and continuous to make an impact in her field. Author at reputed public health platform, she writes to promote health awareness. Recognised for her exceptional contributions, she is a multiple-time government R&D grant recipient, particularly in neurodegenerative disorder studies.

4

Nanotechnology based Drug Delivery for Infectious Diseases

Dr. Vinod Kumar Rajana

Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.

5

Generative AI and the New Era of Personalized Medicine

Uddalak Das

Uddalak Das, PhD scholar at IISc Bengaluru, specializes in drug discovery and cancer immunotherapeutics. With 20+ publications, a patent, and collaborations with institutes like NCBS, JNU, and inStem, he advances green healthcare solutions. He is a member of AACR and EACR among others and has received multiple national fellowships and research grants.

press releasesRead more...

Asia–US Clinical Data Collaboration Built on IHH's Clinical Data

Mitsui Co Ltd Mitsui Head Office Tokyo President and CEO Kenichi Hori has entered a service agreement with Oncoshot Pte Ltd Oncoshot on the utilization of Oncoshots proprietary clinical

Teijin, Teijin Regenet and Shinshu University Hospital Launch Joint Research to Strengthen CAR-T Cell Therapy Manufacturing Capabilities in Japan

Teijin Limited Teijin Regenet Co Ltd and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene

VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence

Viral Vector Manufacturing Facility Pty Ltd VVMF Australias first viral vector Contract Development and Manufacturing Organisation CDMO advises that the Therapeutic Goods Administration TGA

Oral insulin drug achieves a critical milestone

University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

Transcenta Therapeutics HKEX a global clinicalstage biopharmaceutical company with fully integrated capabilities in discovery RD and process development of antibodybased therapeutics

1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China

cBio a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases and Lees Pharmaceutical

EventsRead more...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

CordenPharma Expands Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Annually

CordenPharma is expanding its sterile injectable manufacturing capacity at its Caponago site in Milan Italy through a multiyear investment programme

Exegenesis Bio Enters into Collaboration with Modalis to Advance MDL-201 for Duchenne Muscular Dystrophy

Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL an investigational treatment for Duchenne muscular dystrophy DMD

Schrödinger Forms Tectora Therapeutics to Advance Immunology and Inflammation Programmes

Schrdinger has announced the formation of Tectora Therapeutics The company was cofounded by Schrdinger New Enterprise Associates NEA and RA Capital Management

MannKind and Rose Pharma Partner to Develop Inhaled GLP-1 for Weight Management

MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE Technosphere an investigational inhaled GLP therapy for weight management

Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances

Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical

ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease

Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients